公开(公告)号：US12109308B2

公开(公告)日：2024-10-08

申请号：US15734147

申请日：2019-06-04

Applicant: Pfizer Inc.

Inventor： James Joseph Hussey ,  Andrew Gilbert Bright

IPC: A61K9/08 ,  A61K9/00 ,  A61K9/19 ,  A61K31/5377 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K47/40 ,  A61P35/00

CPC classification number: A61K9/08 ,  A61K9/0019 ,  A61K9/19 ,  A61K31/5377 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K47/40 ,  A61P35/00

Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable organic or inorganic acid salt thereof, a pharmaceutically acceptable organic or inorganic acid, a pharmaceutically acceptable beta- or gamma-cyclodextrin and water, that is a clear solution, with the proviso that the organic or inorganic acid (including a salt thereof) is not a sulphonic acid. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.

公开(公告)号：US20250064732A1

公开(公告)日：2025-02-27

申请号：US18825795

申请日：2024-09-05

Applicant: PFIZER INC.

Inventor： James Joseph HUSSEY ,  Andrew Gilbert Bright

IPC: A61K9/08 ,  A61K9/00 ,  A61K9/19 ,  A61K31/5377 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K47/40 ,  A61P35/00

Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable organic or inorganic acid salt thereof, a pharmaceutically acceptable organic or inorganic acid, a pharmaceutically acceptable beta- or gamma-cyclodextrin and water, that is a clear solution, with the proviso that the organic or inorganic acid (including a salt thereof) is not a sulphonic acid. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.

公开(公告)号：US20210212944A1

公开(公告)日：2021-07-15

申请号：US15734147

申请日：2019-06-04

Applicant: Pfizer Inc.

Inventor： James Joseph Hussey ,  Andrew Gilbert Bright

IPC: A61K9/08 ,  A61K31/5377 ,  A61K47/12 ,  A61K47/40 ,  A61K47/02 ,  A61K9/19 ,  A61K9/00

Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-enyl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable organic or inorganic acid salt thereof, a pharmaceutically acceptable organic or inorganic acid, a pharmaceutically acceptable beta- or gamma-cyclodextrin and water, that is a clear solution, with the proviso that the organic or inorganic acid (including a salt thereof) is not a sulphonic acid. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.

公开(公告)号：US11541058B2

公开(公告)日：2023-01-03

申请号：US16641045

申请日：2018-08-20

Applicant: PFIZER INC.

Inventor： James Joseph Hussey ,  Andrew Gilbert Bright

IPC: A61K31/5377 ,  A61K9/08 ,  A61K9/19 ,  A61K47/40 ,  A61K47/20 ,  A61K9/00 ,  A61K47/26

Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable alkanesulphonate salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.

公开(公告)号：US20210267988A1

公开(公告)日：2021-09-02

申请号：US16641045

申请日：2018-08-20

Applicant: PFIZER INC.

Inventor： James Joseph Hussey ,  Andrew Gilbert Bright

IPC: A61K31/5377 ,  A61K9/08 ,  A61K9/19 ,  A61K47/40 ,  A61K47/20 ,  A61K9/00 ,  A61K47/26

Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable alkanesulphonate salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.